title: Prognostic stratification improvement by integrating ID1/ID3/IGJ gene expression signature and immunophenotypic profile in adult patients with B-ALL.
abstract: Survival of adults with B-Acute Lymphoblastic Leukemia requires accurate risk stratification of patients in order to provide the appropriate therapy. Contemporary techniques, using clinical and cytogenetic variables are incomplete for prognosis prediction.
  
  
  
  To improve the classification of adult patients diagnosed with B-ALL into prognosis groups, two strategies were examined and combined: the expression of the ID1/ID3/IGJ gene signature by RT-PCR and the immunophenotypic profile of 19 markers proposed in the EuroFlow protocol by Flow Cytometry in bone marrow samples.
  
  
  
  Both techniques were correlated to stratify patients into prognostic groups. An inverse relationship between survival and expression of the three-genes signature was observed and an immunophenotypic profile associated with clinical outcome was identified. Markers CD10 and CD20 were correlated with simultaneous overexpression of ID1, ID3 and IGJ. Patients with simultaneous expression of the poor prognosis gene signature and overexpression of CD10 or CD20, had worse Event Free Survival and Overall Survival than patients who had either the poor prognosis gene expression signature or only CD20 or CD10 overexpressed.
  
  
  
  By utilizing the combined evaluation of these two immunophenotypic markers along with the poor prognosis gene expression signature, the risk stratification can be significantly strengthened. Further studies including a large number of patients are needed to confirm these findings.
authors.affiliation: Programa de Investigación e Innovación en Leucemias Agudas y Crónicas (PILAC), Instituto Nacional de Cancerología, Bogotá, Colombia.|Grupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá, Colombia.|Programa de Doctorado en Ciencias Biológicas, Pontificia Universidad Javeriana, Bogotá, Colombia.
authors.forename: Nataly
authors.initials: N
authors.lastname: Cruz-Rodriguez
authors.affiliation: Programa de Investigación e Innovación en Leucemias Agudas y Crónicas (PILAC), Instituto Nacional de Cancerología, Bogotá, Colombia. acombita@cancer.gov.co.|Grupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá, Colombia. acombita@cancer.gov.co.|Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, Colombia. acombita@cancer.gov.co.
authors.forename: Alba L
authors.initials: AL
authors.lastname: Combita
authors.affiliation: Programa de Investigación e Innovación en Leucemias Agudas y Crónicas (PILAC), Instituto Nacional de Cancerología, Bogotá, Colombia.|Grupo de Hemato-Oncología, Instituto Nacional de Cancerología, Bogotá, Colombia.
authors.forename: Leonardo J
authors.initials: LJ
authors.lastname: Enciso
authors.affiliation: Department of Pediatrics, Pediatric Hematology-Oncology Louisiana State University Health Sciences Center, New Orleans, LA, USA.|Children's Hospital of New Orleans, New Orleans, LA, USA.
authors.forename: Lauren F
authors.initials: LF
authors.lastname: Raney
authors.affiliation: Grupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá, Colombia.
authors.forename: Paula L
authors.initials: PL
authors.lastname: Pinzon
authors.affiliation: Grupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá, Colombia.
authors.forename: Olga C
authors.initials: OC
authors.lastname: Lozano
authors.affiliation: Hospital Universitario San Ignacio, Bogotá, Colombia.
authors.forename: Alba M
authors.initials: AM
authors.lastname: Campos
authors.affiliation: Hospital Universitario San Ignacio, Bogotá, Colombia.
authors.forename: Niyireth
authors.initials: N
authors.lastname: Peñaloza
authors.affiliation: Hospital Universitario San Ignacio, Bogotá, Colombia.
authors.forename: Julio
authors.initials: J
authors.lastname: Solano
authors.affiliation: Hospital Universitario San Ignacio, Bogotá, Colombia.
authors.forename: Maria V
authors.initials: MV
authors.lastname: Herrera
authors.affiliation: Department of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.|Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
authors.forename: Jovanny
authors.initials: J
authors.lastname: Zabaleta
authors.affiliation: Hospital Universitario San Ignacio, Bogotá, Colombia. squijano@javeriana.edu.co.|Grupo de Inmunobiología y Biología Celular, Departamento de Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, Colombia. squijano@javeriana.edu.co.
authors.forename: Sandra
authors.initials: S
authors.lastname: Quijano
mesh_terms: D000293:Adolescent; D000328:Adult; D018951:Antigens, CD20 / Q000378:metabolism*; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007144:Immunoglobulin J-Chains / Q000235:genetics*; D016130:Immunophenotyping; D051798:Inhibitor of Differentiation Protein 1 / Q000235:genetics*; D051796:Inhibitor of Differentiation Proteins / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics*; D015260:Neprilysin / Q000378:metabolism*; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000145:classification* / Q000235:genetics / Q000276:immunology; D011379:Prognosis; D016019:Survival Analysis; D055815:Young Adult
chemical_list: D018951:Antigens, CD20; C497453:ID1 protein, human; D007144:Immunoglobulin J-Chains; D051798:Inhibitor of Differentiation Protein 1; D051796:Inhibitor of Differentiation Proteins; D009363:Neoplasm Proteins; C075640:ID3 protein, human; D015260:Neprilysin
keywords: B-ALL; Gene-expression; Immunophenotype; Risk-stratification; Survival